Notable Alums
Specialty: Psychiatry
Graduation Year: 1985
John Newcomer
John Newcomer, M.D., is the vice dean for Research and Innovation and Professor of Integrated Medical Science for Florida Atlantic University’s Charles E. Schmidt College of Medicine. He oversees the college’s research and development programs, and its graduate training programs.
Dr. Newcomer has served as a principal investigator on research grants funded through the National Institutes of Health for more than 20 years, and has held a series of research leadership positions at Washington University in St. Louis, the University of Miami in Florida, and at FAU, where he served as interim vice president for Research in 2014.
Dr. Newcomer has received a number of honors and awards, including an Independent Scientist Award from the NIH, and placement on the Thomson Reuters List of Highly Cited Researchers in 2014. A longstanding reviewer for the NIH and other funding agencies, he has been a member of the Metabolic Disorders Steering Committee of the Biomarkers Consortium of the Foundation for the National Institutes of Health since 2007.
In the public sector, for 13 years he was chair of the Medicaid Drug Utilization Review Board for the state of Missouri, supporting public oversight for more than $1 billion in pharmacy program expenditures.
Dr. Newcomer has served as a principal investigator on research grants funded through the National Institutes of Health for more than 20 years, and has held a series of research leadership positions at Washington University in St. Louis, the University of Miami in Florida, and at FAU, where he served as interim vice president for Research in 2014.
Dr. Newcomer has received a number of honors and awards, including an Independent Scientist Award from the NIH, and placement on the Thomson Reuters List of Highly Cited Researchers in 2014. A longstanding reviewer for the NIH and other funding agencies, he has been a member of the Metabolic Disorders Steering Committee of the Biomarkers Consortium of the Foundation for the National Institutes of Health since 2007.
In the public sector, for 13 years he was chair of the Medicaid Drug Utilization Review Board for the state of Missouri, supporting public oversight for more than $1 billion in pharmacy program expenditures.